Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)
Recruiting now · Not applicable
Conditions studied: Myelodysplastic Syndromes, Ferroptosis
In brief
Myelodysplastic syndromes (MDS) are clonal diseases of hematopoietic stem cells (HSC) characterized by dysplastic and inefficient hematopoiesis related to excessive progenitor cell death. Ferroptosis is a recently described cell death mechanism and we think that it could be a major player in the pathophysiology of MDS, involved in the cell death that characterizes these diseases and contributing to cytopenias. The study aims to demonstrate that there is a significant activation of this phenomenon in MDS patients compared to a population of subjects without MDS.
Key facts
- Study ID
- NCT05924074
- Run by
- University Hospital, Bordeaux
- People needed
- 80
- Starts
- 2025-02-21
- Expected to finish
- 2027-02-01
- Last updated by the study team
- 2025-03-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- For all :
- Patients of legal age (age ≥ 18 years)
- Subjects affiliated to or benefiting from a social security scheme
- Free, written and informed consent signed by the participant and the investigator
- For MDS patients :
- Sampling at diagnosis for MDS patients (WHO 2016 criteria)
- Presence of ring sideroblasts on bone marrow smear
- For MGUS patients :
- Sampling as part of the exploration of monoclonal gammopathy of undetermined significance (MGUS) for controls (WHO 2016 criteria).
You may not qualify if…
- For all
- Patient transfused with red blood cells within 120 days prior to collection
- Patients treated with haematopoietic growth factors (EPO, TPO, G-CSF) within 30 days prior to collection
- Patients with conditions that affect systemic iron metabolism: hemochromatosis, Gaucher disease, ferroportin disease, porphyria cutanea tarda
- Person under a legal protection measure (legal protection, guardianship or curatorship)
- Person deprived of liberty by judicial or administrative decision
- Person who is unable to give consent
- Subject who is in an exclusion period after another study or who has participated in another interventional drug study within 30 days prior to entry into the protocol
Where it is running
- CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire — Pessac, France (enrolling)
- CHU de Bordeaux, Laboratoire d'Hématologie — Pessac, France
- CHU de Bordeaux, Service de Médecine Interne — Pessac, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.